JoElleng  Lyons Dillon net worth and biography

JoElleng Lyons Dillon Biography and Net Worth

Director of Viatris

JoEllen Lyons Dillon joined the Viatris board of directors in 2020 after six years of service on the Mylan board. 

Ms. Dillon previously served as an executive officer of The ExOne Company ("ExOne"). ExOne was a global provider of three-dimensional (3D) printing machines and printed products, materials and other services to industrial customers creating products in metal on a worldwide basis and merged with Desktop Metal in November 2021. After serving as ExOne's chief legal officer and corporate secretary, she became the company's executive vice president of strategic developments and capital markets. Prior to joining ExOne, Ms. Dillon was a legal consultant on that company’s initial public offering, following having a nearly 25-year legal career as a partner with the law firms of Buchanan Ingersoll & Rooney PC and Reed Smith LLP.

Ms. Dillon’s qualifications to serve on the Board include, among others, her experience regarding public company management, corporate governance, finance, accounting and capital markets, global business, human capital management, information security, legal and regulatory oversight, risk oversight and compliance, and strategy and M&A, which she gained during her almost 25-year legal career in corporate mergers and acquisitions and securities, where she represented both public and private companies in a variety of complex matters, and further developed while at ExOne, where she was responsible for capital markets development, corporate strategic planning, human resources including oversight of DEI, global compliance, investor relations, and international business development within Europe and Asia through which she became a thought leader in the areas of corporate governance, legal and regulatory oversight, capital markets and M&A and is regularly invited to speak at major conferences on such topics. Ms. Dillon also brings corporate social responsibility experience to the Board obtained through her legal and regulatory background, in addition to ongoing education programs.

What is JoElleng Lyons Dillon's net worth?

The estimated net worth of JoElleng Lyons Dillon is at least $769,153.40 as of March 5th, 2024. Ms. Lyons Dillon owns 58,714 shares of Viatris stock worth more than $769,153 as of December 3rd. This net worth estimate does not reflect any other assets that Ms. Lyons Dillon may own. Learn More about JoElleng Lyons Dillon's net worth.

How do I contact JoElleng Lyons Dillon?

The corporate mailing address for Ms. Lyons Dillon and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on JoElleng Lyons Dillon's contact information.

Has JoElleng Lyons Dillon been buying or selling shares of Viatris?

JoElleng Lyons Dillon has not been actively trading shares of Viatris within the last three months. Most recently, Dillon Joellen Lyons sold 20,000 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $12.36, for a transaction totalling $247,200.00. Following the completion of the sale, the director now directly owns 58,714 shares of the company's stock, valued at $725,705.04. Learn More on JoElleng Lyons Dillon's trading history.

Who are Viatris' active insiders?

Viatris' insider roster includes Paul Campbell (CAO and Corporate Controller), W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), JoElleng Lyons Dillon (Director), Rajiv Malik (Director), Brian Roman (Chief Legal Officer), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.

Are insiders buying or selling shares of Viatris?

During the last twelve months, insiders at the sold shares 15 times. They sold a total of 952,038 shares worth more than $11,111,759.37. The most recent insider tranaction occured on November, 11th when insider Paul Campbell sold 26,925 shares worth more than $346,794.00. Insiders at Viatris own 0.1% of the company. Learn More about insider trades at Viatris.

Information on this page was last updated on 11/11/2024.

JoElleng Lyons Dillon Insider Trading History at Viatris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2024Sell20,000$12.36$247,200.0058,714View SEC Filing Icon  
See Full Table

JoElleng Lyons Dillon Buying and Selling Activity at Viatris

This chart shows Dillon Joellen Lyons's buying and selling at Viatris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Viatris Company Overview

Viatris logo
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Read More

Today's Range

Now: $13.10
Low: $13.03
High: $13.23

50 Day Range

MA: $12.07
Low: $11.27
High: $13.37

2 Week Range

Now: $13.10
Low: $9.31
High: $13.62

Volume

1,203,644 shs

Average Volume

8,535,212 shs

Market Capitalization

$15.64 billion

P/E Ratio

N/A

Dividend Yield

3.67%

Beta

0.96